Reporter, Washington, DC
Susan's Feed
Apr 10, 2014
Apr 10, 2014
Apr 10, 2014
Apr 10, 2014

U.S. drug industry group defends price of Gilead hepatitis drug

WASHINGTON (Reuters) – The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc’s new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

“Their lives, in short, will be transformed,” Pharmaceutical Research and Manufacturers of America (PhRMA) President John Castellani said at the group’s annual meeting in Washington. “The value to these patients, and to their loved ones and society – you can’t put a price tag on it.”

Apr 10, 2014
Apr 9, 2014
Apr 9, 2014
Apr 9, 2014
Apr 9, 2014
Apr 9, 2014